Effect of methylphenidate formulation on treatment patterns and use of emergency room services

American Journal of Health-System Pharmacy

Volumn 63, Issue 4, 2006, Pages 317-322

  Kemner, Jason E ^a   Lage, Maureen J ^b  

^a Medical Science Liaison   (United States)

^b HealthMetrics Outcomes Research LLC   (United States)

Author keywords

Attention deficit disorder with hyperactivity; Central nervous system stimulants; Compliance; Dosage schedules; Drug use; Formulations; Hospitals; Methylphenidate; Patients; Release; Sustained action medications

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DATA BASE; DRUG COST; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG RELEASE; DRUG SUBSTITUTION; DRUG USE; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; REGRESSION ANALYSIS; SUSTAINED RELEASE PREPARATION; TREATMENT DURATION;

EID: 32644441092     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050129     Document Type: Article

References (40)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105:1158-70.
2. Daley KC. Update on attention-deficit/hyperactivity disorder. Curr Opin Pediatr. 2004; 16:217-26.
3. Barkley RA, Fischer M, Smallish L et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004; 45:195-211.
4. Rowe R, Maughan B, Goodman R. Childhood psychiatric disorder and unintentional injury: findings from a national cohort study. J Pediatr Psychol. 2004; 29:119-30.
5. Barkley RA, Murphy KR, Dupaul GI et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002; 8:655-72.
6. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996; 98(6, pt. 1):1089-95.
7. Barkley RA, Guevremont DC, Anastopoulos AD et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993; 92:212-8.
8. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001;931:1-16.
9. Hill JC, Schoener EP. Age-dependent decline in attention deficit hyperactivity disorder. Am J Psychiatry. 1996; 153:1143-6.
10. Leibson CL, Katusic SK, Barbaresi WJ et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001; 285:60-6.
11. Zeitlin H. Continuities of childhood disorders into adulthood. In: Reder P, McClure M, Jolly A, eds. Family matters: interfaces between child and adult mental health. London, England: Routledge; 2000:21-37.
12. Curran S, Fitzgerald M. Attention deficit hyperactivity disorder in the prison population. Am J Psychiatry. 1999; 156:1664-5. Letter.
13. Muslow MH, O'Neal KK, Murry VM. Adult attention deficit hyperactivity disorder, the family, and child maltreatment. Trauma Violence Abuse. 2001; 2:36-50.
14. Seidman LJ, Biederman J, Weber W et al. Neuropsychological function in adults with attention deficit hyperactivity disorder. Biol Psychiatry. 1998; 44:260-8.
15. Selke JH. Adults with ADHD in the workplace: a descriptive analysis and evaluation of the workplace and job satisfaction. Berkeley, CA: University of California Berkeley, 2000. Dissertation.
16. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry. 1996; 37:393-401.
17. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001; 108:1033-44.
18. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse events. J Am Acad Child Adolesc Psychiatry. 2004; 43:559-67.
19. Aron AR, Dowson JH, Sahakian BJ et al. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2003; 54:1465-8.
20. Marks DJ, Newcorn JH, Halperin JM. Comorbidity in adults with attention-deficit/hyperactivity disorder. Ann N Y Acad Sci. 2001; 931:216-38.
21. Alpert JE, Maddocks A, Nierenberg AA et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996; 62:213-9.
22. Biederman J, Faraone SV, Spencer T et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993; 150:1792-8.
23. Ratey JJ, Greenberg MS, Bemporad JR et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol. 1992; 2:267-75.
24. Shekim WO, Asarnow RF, Hess E et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990; 31:416-25.
25. Greene WH. Econometric analysis. Upper Saddle River, NJ: Prentice Hall; 2003:744-5.
26. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol. 2001; 11:59-67.
27. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003; 17:117-31.
28. Ibrahim el SR. Rates of adherence to pharmacological treatment among children and adolescents with attention deficit hyperactivity disorder. Hum Psychopharmacol. 2002; 17:225-31.
29. Perwien A, Hall J, Swensen A et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm. 2004; 10:122-9.
30. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23:1296-310.
31. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol. 2004; 14:575-81.
32. Loosbrock DL, Zhao Z, Johnstone BM et al. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ. 2003; 6:67-75.
33. DeBar LL, Lynch FL, Boles M. Healthcare use by children with attention deficit/hyperactivity disorder with and without psychiatric conditions. J Behav Health Serv Res. 2004; 31:312-23.
34. Wilson L. Turning down the volume. More commitment to primary care has helped reduce ER visits. Mod Healthc. 2004; Jul 26:suppl 12.
35. Williams RM. The cost of visits to emergency departments. N Engl J Med. 1996; 334:642-6.
36. Cherpitel CJ, Bond J, Ye Y et al. Alcohol-related injury in the ER: a cross-national meta-analysis from the Emergency Room Collaborative Alcohol Analysis Project (ERCAAP). J Stud Alcohol. 2003; 64:641-9.
37. McGeary KA, French MT. Illicit drug use and emergency room utilization. Health Serv Res. 2000; 35(1, pt. 1):153-69.
38. Cherpitel CJ. Emergency room and primary care services utilization and associated alcohol and drug use in the United States general population. Alcohol Alcohol. 1999; 34:581-9.
39. Cornelius LJ. Ethnic minorities and access to medical care: where do they stand? J Assoc Acad Minor Phys. 1993; 4:16-25.
40. [Erratum, J Assoc Acad Minor Phys. 1993; 4:66.]